Sabrina A. Hogan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sabrina A. Hogan has a total of 293 co-authors. Here are the top co-authors by number of shared publications:
- Mitchell Paul Levesque
Department of Dermatology, University of Zurich, University Hospital Zurich, Zurich, Switzerland
35 shared publications - Phil Fang Cheng
Department of Dermatology, University of Zurich Hospital and Faculty of Medicine, University of Zurich, Zurich, Switzerland
35 shared publications - Reinhard Dummer
Department of Dermatology, University Hospital Zürich, University of Zurich, 8091 Zurich, Switzerland
32 shared publications Mitchell P. Levesque
29 shared publications- Gregor Hutter
Department of Biomedicine, Basel University Hospital, Basel, Switzerland
22 shared publications - Adelheid Elbe-Bürger
Medical University of Vienna
21 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Myeloid panel for tumor immune characterisation of the KPC model.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Myeloid panel for tumor immune characterisation of the KPC model.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Lymphoid panel for tumor immune characterisation of the KPC model.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Lymphoid panel for tumor immune characterisation of the KPC model.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Data from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Current immunotherapies often fail in immunologically “cold,” macrophage-rich tumor microenvironments (TME). Multitargeting approaches that modulate innate-adaptive immune activation represent a promising frontier in cancer immunotherapy. In this study, we developed phagocytic synapse enhancers (PSE), a class of modular immune engagers comprising a high-affinity PD-L1 binder coupled to a macrophage-stimulating peptide, tuftsin. PSEs strengthened effector–target cell interactions and enhanced tumor phagocytosis by bridging tumor PD-L1 to macrophage neuropilin-1, bypassing the classic FcγR-dependent pathways. The PSEs also acted in cis on PD-L1+ macrophages, accelerating the endocytosis and lysosomal compartmentalization of surface PD-L1 and therefore stripping the immunosuppressive checkpoint from the local microenvironment. Beyond physical clearance, the PSEs reprogrammed macrophage phenotype and triggered a robust proinflammatory cytokine and chemokine response. The lead molecule, longPSE, and its half-life–extended variant fused to the albumin-binding domain, ABD-longPSE, showcased superior efficacy than the macrophage enhancer magrolimab in a syngeneic tumor model of colorectal cancer and an orthotopic model of pancreatic cancer. PSE treatment remodeled the TME by inducing phenotypic changes in the lymphoid and myeloid compartments, together with a reduction of tumor-associated macrophages and regulatory T cells. These findings establish PSEs as bifunctional molecules that complement innate and adaptive immune modulation. The bifunctional design offers a versatile approach for next-generation immunotherapies and provides a blueprint for a plug-and-play platform of immune engagers targeting diverse cancer-associated pathways. Significance:Bifunctional immune modulators that simultaneously boost phagocytosis and block immune checkpoints offer a versatile strategy to reprogram the tumor microenvironment and advance next-generation cancer immunotherapy.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Current immunotherapies often fail in immunologically “cold,” macrophage-rich tumor microenvironments (TME). Multitargeting approaches that modulate innate-adaptive immune activation represent a promising frontier in cancer immunotherapy. In this study, we developed phagocytic synapse enhancers (PSE), a class of modular immune engagers comprising a high-affinity PD-L1 binder coupled to a macrophage-stimulating peptide, tuftsin. PSEs strengthened effector–target cell interactions and enhanced tumor phagocytosis by bridging tumor PD-L1 to macrophage neuropilin-1, bypassing the classic FcγR-dependent pathways. The PSEs also acted in cis on PD-L1+ macrophages, accelerating the endocytosis and lysosomal compartmentalization of surface PD-L1 and therefore stripping the immunosuppressive checkpoint from the local microenvironment. Beyond physical clearance, the PSEs reprogrammed macrophage phenotype and triggered a robust proinflammatory cytokine and chemokine response. The lead molecule, longPSE, and its half-life–extended variant fused to the albumin-binding domain, ABD-longPSE, showcased superior efficacy than the macrophage enhancer magrolimab in a syngeneic tumor model of colorectal cancer and an orthotopic model of pancreatic cancer. PSE treatment remodeled the TME by inducing phenotypic changes in the lymphoid and myeloid compartments, together with a reduction of tumor-associated macrophages and regulatory T cells. These findings establish PSEs as bifunctional molecules that complement innate and adaptive immune modulation. The bifunctional design offers a versatile approach for next-generation immunotherapies and provides a blueprint for a plug-and-play platform of immune engagers targeting diverse cancer-associated pathways. Significance:Bifunctional immune modulators that simultaneously boost phagocytosis and block immune checkpoints offer a versatile strategy to reprogram the tumor microenvironment and advance next-generation cancer immunotherapy.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S1 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Binding characterization of PSEs to PD-L1-expressing tumor cells.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S1 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Binding characterization of PSEs to PD-L1-expressing tumor cells.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S2 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Specific binding mechanisms of the tuftsin peptide.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S2 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Specific binding mechanisms of the tuftsin peptide.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Distinct internalization dynamics of the PSE between macrophages and tumor cells.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Distinct internalization dynamics of the PSE between macrophages and tumor cells.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Demonstrates the platform's modularity by introducing and characterizing an EGFR-targeting PSE.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Demonstrates the platform's modularity by introducing and characterizing an EGFR-targeting PSE.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S6 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Synthesis and extensive in vitro screening of a larger library of nanobody-based and de novo binder-based PSEs.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S6 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
Synthesis and extensive in vitro screening of a larger library of nanobody-based and de novo binder-based PSEs.
- Open Access
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
In vivo reprogramming of tumor-associated macrophages using a transgenic zebrafish xenograft model.
- 16 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from Bifunctional Phagocytic Synapse Enhancers Remodel the Tumor Microenvironment to Overcome Immunosuppression
In vivo reprogramming of tumor-associated macrophages using a transgenic zebrafish xenograft model.